Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead Dr. Shannon Westin (MD Anderson Cancer Center, Houston, TX) and Dr. Ramez Eskander (University of

NVCT

Earnings

Regulus Therapeutics’s Earnings: A Preview

By Benzinga Insights

Today, 10:34 PM

Regulus Therapeutics (NASDAQ:RGLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts estimate that Regulus Therapeutics will report an earnings per share (EPS) of $-0.07.

RGLS

Reported Late Wednesday March 08, LSI Industries Introduces Strategic Plan Update, 5-Year Financial Targets; “Fast Forward” Strategy To Deliver $800M In Net Sales And $100M Adjusted EBITDA By FY28; Sees FY23 Revenue $490M-$500M Vs $496.88M Est

By Happy Mohamed

Today, 10:34 PM

"Fast Forward" Strategy to Deliver $800 million in Net Sales and $100 million Adjusted EBITDA by FY28 LSI Industries Inc. (NASDAQ:LYTS, ", LSI", or the ", Company", )))) a

LYTS

Loop Capital Maintains Hold on Mohawk Industries, Raises Price Target to $190

Related Posts

Strong Club Med Results Fail to Lift Fosun Tourism Back to Profits

Nuvectis Pharma Announces Collaboration With ENGOT And GOG Foundation To Conduct The NXP800 Phase 1b Clinical Trial In ARID1A-Mutated Ovarian Carcinoma In Europe And In The U.S.

Regulus Therapeutics’s Earnings: A Preview

Reported Late Wednesday March 08, LSI Industries Introduces Strategic Plan Update, 5-Year Financial Targets; “Fast Forward” Strategy To Deliver $800M In Net Sales And $100M Adjusted EBITDA By FY28; Sees FY23 Revenue $490M-$500M Vs $496.88M Est